(2-甲基咪唑并[2,1-b]噻唑-6-基)甲胺 | 518064-25-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (2-甲基咪唑并[2,1-b]噻唑-6-基)甲胺
• 英文名称: 1-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)methanamine
• 英文别名: (2-methylimidazo[2,1-b][1,3]thiazol-6-yl)methanamine
• CAS: 518064-25-0
• 化学式: C₇H₉N₃S
• mdl: MFCD11506342
• 分子量: 167.235
• InChiKey: KSLLZRAYBKILAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  Boc-O-叔丁基-L-酪氨酸 、 (2-甲基咪唑并[2,1-b]噻唑-6-基)甲胺 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以2.01 g的产率得到O-(1,1-dimethylethyl)-N-{[(1,1-dimethylethyl)oxy]carbonyl}-N-[(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)methyl]-L-tyrosinamide
  参考文献：
  名称：

  发现新型长效毒蕈碱型乙酰胆碱受体拮抗剂。

  摘要：

  高通量筛选和随后的优化导致发现新型季铵盐作为具有出色选择性的高效毒蕈碱型乙酰胆碱受体拮抗剂。在两种物种中，通过鼻内或气管内给药，化合物8a，13a和13b在两个物种的体内支气管收缩模型中显示出出色的抑制活性和长效作用。新型吸入毒蕈碱受体拮抗剂是潜在的有用的治疗剂，用于治疗慢性阻塞性肺疾病和其他支气管收缩疾病。

  DOI：

  10.1021/jm800634k
• 作为产物：
  描述：

  6-(azidomethyl)-2-methylimidazo[2,1-b][1,3]thiazole 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 生成 (2-甲基咪唑并[2,1-b]噻唑-6-基)甲胺
  参考文献：
  名称：

  发现新型长效毒蕈碱型乙酰胆碱受体拮抗剂。

  摘要：

  高通量筛选和随后的优化导致发现新型季铵盐作为具有出色选择性的高效毒蕈碱型乙酰胆碱受体拮抗剂。在两种物种中，通过鼻内或气管内给药，化合物8a，13a和13b在两个物种的体内支气管收缩模型中显示出出色的抑制活性和长效作用。新型吸入毒蕈碱受体拮抗剂是潜在的有用的治疗剂，用于治疗慢性阻塞性肺疾病和其他支气管收缩疾病。

  DOI：

  10.1021/jm800634k

文献信息

• WO2006/65755
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis of secondary and tertiary aminofurazans
  作者：A. B. Sheremetev、V. G. Andrianov、E. V. Mantseva、E. V. Shatunova、N. S. Aleksandrova、I. L. Yudin、D. E. Dmitriev、B. B. Averkiev、M. Yu. Antipin

  DOI：10.1023/b:rucb.0000035644.16331.f0

  日期：2004.3

  Reactions of nitrofurazans with primary and secondary amines were studied. Conditions were found which allow the efficient replacement of the nitro group with these nucleophiles. Transformations of the amidoxime fragment, which is bound to the furazan ring and contains an amino substituent, enable one to substantially expand the spectrum of polyfunctional derivatives. The structures of the amines synthesized were studied by X-ray diffraction analysis.
• Maximizing Diversity from a Kinase Screen: Identification of Novel and Selective pan-Trk Inhibitors for Chronic Pain
  作者：Shawn J. Stachel、John M. Sanders、Darrell A. Henze、Mike T. Rudd、Hua-Poo Su、Yiwei Li、Kausik K. Nanda、Melissa S. Egbertson、Peter J. Manley、Kristen L. G. Jones、Edward J. Brnardic、Ahren Green、Jay A. Grobler、Barbara Hanney、Michael Leitl、Ming-Tain Lai、Vandna Munshi、Dennis Murphy、Keith Rickert、Daniel Riley、Alicja Krasowska-Zoladek、Christopher Daley、Paul Zuck、Stephanie A. Kane、Mark T. Bilodeau

  DOI：10.1021/jm5006429

  日期：2014.7.10

  We have identified several series of small molecule inhibitors of TrkA with unique binding modes. The starting leads were chosen to maximize the structural and binding mode diversity derived from a high throughput screen of our internal compound collection. These leads were optimized for potency and selectivity employing a structure based drug design approach adhering to the principles of ligand efficiency to maximize binding affinity without overly relying on lipophilic interactions. This endeavor resulted in the identification of several small molecule pan-Trk inhibitor series that exhibit high selectivity for TrkA/B/C versus a diverse panel of kinases. We have also demonstrated efficacy in both inflammatory and neuropathic pain models upon oral dosing. Herein we describe the identification process, hit-to-lead progression, and binding profiles of these selective pan-Trk kinase inhibitors.
• WO2006/65788
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE
  申请人：MERCK & CO INC

  公开号：WO2003035615A2

  公开（公告）日：2003-05-01

  The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a 2-carboxy pyrrole. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.